The preventive and protective role of melatonin in SARS-CoV-2 infection: a retrospective study

Melatonin protection in COVID-19

  • Antonio Molina-Carballo Department of Pediatrics. School of Medicine. University of Granada. Spain
  • Antonio Emilio Jerez-Calero Department of Pediatrics. School of Medicine. University of Granada. Spain
  • Luisa Fernández-López Department of Pediatrics. School of Medicine. University of Granada. Spain
  • María del Carmen Augustin-Morales Health Center “Las Gabias”. Metropolitan District. Granada. Spain
  • Antonio Muñoz-Hoyos Department of Pediatrics. School of Medicine. University of Granada. Spain
  • Ahmad Agil Department of Pharmacology, Biohealth Institute and Neurosciences Institute, School of Medicine, University of Granada, 18016 Granada, Spain
Keywords: COVID-19, SARS-CoV-2, melatonine, infection, retrospective study

Abstract

This study has investigated the protective role of melatonin against SARS-CoV-2 infection. For this purpose, 62 adults were recruited who were in  daily relatively high doses of melatonin intaking, with the particularity that they started taking it before the beginning of the COVID-19 pandemic and  continued to present. A continuous validation process has been carried out with a series of questionnaires to identify the risk factors, whether they were contacts, were infected, if yes, the level of disease severity, need for treatment, hospitalization, etc. According to the dose of melatonin the individuals took/are taking, they were divided into two groups: a) those taking 20 mg (n = 27) and, b) those taking ≥ 40 mg (n = 32). For statistical analysis, the shi2 test and Fisher's exact test were used. The number of infected subjects with positive PCR was 7 (11.9%). Only one required medication, the rest had a very favorable clinical evolution, mild in three cases and asymptomatic in three others. While in their environment this percentage is 22.05% (chi2 = 2.928; p < 0.087). Melatonin offers a good safety profile, is well tolerated and can play an important role in the different levels of COVID-19 prevention.


References

1. Levels of Prevention: Health Education, Advocacy and Community Mobilization Chapter: 4. Human Behaviour and Health: 1.
2. Porta M (2014) A dictionary of epidemiology: Oxford University Press.
3. Leavel HR, Clark EG (1965) Preventive Medicine for the Doctor in His Community. New York, NY: McGraw-Hill.
4. Chen Y, Zhou R, Chen B et al. (2020) Knowledge, perceived beliefs, and preventive behaviors related to COVID-19 among chinese older adults: Cross-sectional web-based survey. J. Med. Internet. Res. 22: e23729.
5. Li Y, Li L, Niu YC et al. (2020) Several considerations on the establishment of a new public health and preventive medicine system in national level. Zhonghua Yu Fang Yi Xue Za Zhi 54: 469-474.
6. Cross KM, Landis DM, Sehgal L et al. (2021) Melatonin for the early treatment of COVID-19: A narrative review of current evidence and possible efficacy. Endocr. Pract. 27: 850-855.
7. Regodón S, Martín-Palomino P, Fernández-Montesinos R et al. (2005) The use of melatonin as a vaccine agent. Vaccine 23: 5321-5327.
8. Regodón S, Ramos A, Míguez MP et al. (2012) Vaccination prepartum enhances the beneficial effects of melatonin on the immune response and reduces platelet responsiveness in sheep. BMC Vet. Res. 8: 84.
9. Regodón S, Ramos A, Morgado S et al. (2009) Melatonin enhances the immune response to vaccination against A1 and C strains of Dichelobacter nodosus. Vaccine 27: 1566-1570.
10. Wang YX, Yang GH, Zhang LL et al. (2021) Melatonin as immune potentiator for enhancing subunit vaccine efficacy against bovine viral diarrhea virus. Vaccines (Basel) 9: 1030.
11. Cardinali DP, Brown GM, Pandi-Perumal SR (2020) Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients? Diseases 8: 44.
12. Kow CS, Ramachandram DS, Hasan SS (2021) Melatonin: Revisited role as vaccine adjuvant during outbreaks of COVID-19 caused by the delta variant. J. Neuroimmune Pharmacol. 17: 425-426.
13. Guerrero JM, Reiter RJ (2002) Melatonin-immune system relationships. Curr. Top. Med. Chem. 2: 167-179.
14. Csaba G (2013) The pineal regulation of the immune system: 40 years since the discovery. Acta Microbiol. Immunol. Hung. 60: 77-91.
15. Carrillo-Vico A, Reiter RJ, Lardone PJ et al. (2006) The modulatory role of melatonin on immune responsiveness. Curr. Opin. Investig. Drugs 7: 423-431.
16. Markus RP, Sousa KS, da Silveira Cruz-Machado S et al. (2021) Possible role of pineal and extra-pineal melatonin in surveillance, immunity, and first-line defense. Int. J. Mol. Sci. 22: 12143.
17. Huggard D, Kelly L, Worrall A et al. (2021) Melatonin as an immunomodulator in children with Down syndrome. Pediatr. Res. 91: 1812-1820.
18. Ramos González EJ, Ramirez Jirano LJ, García Martínez DZ et al. (2021) A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis. Neurologia (Engl Ed) 36: 262-270.
19. Cernysiov V, Gerasimcik N, Mauricas M et al. (2010) Regulation of T-cell-independent and T-cell-dependent antibody production by circadian rhythm and melatonin. Int. Immunol. 22: 25-34.
20. NaveenKumar SK, Hemshekhar M, Jagadish S et al. (2020) Melatonin restores neutrophil functions and prevents apoptosis amid dysfunctional glutathione redox system. J. Pineal Res. 69: e12676.
21. Sánchez-González M, Mahíllo-Fernández I, Villar-Álvarez F et al. (2022) What if melatonin could help patients with severe COVID-19? J. Clin. Sleep Med. 18: 335-336.
22. Ameri A, Asadi MF, Kamali M et al. (2021) Evaluation of the effect of melatonin in patients with COVID-19-induced pneumonia admitted to the Intensive Care Unit: A structured summary of a study protocol for a randomized controlled trial. Trials 22: 194.
23. Tan DX, Reiter RJ (2022) Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality. Life Sci, 294: 120368.
24. Ramlall V, Zucker J, Tatonetti N (2020) Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv. PMID: 33083812.
25. Chitimus DM, Popescu MR, Voiculescu SE et al. (2020) Melatonin's impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease. Biomolecules 10: 1211.
26. Nair AS (2022) Perioperative melatonin in COVID-19 patients: benefits beyond sedation and analgesia. Med. Gas Res. 12: 41-43.
27. Mousavi SA, Heydari K, Mehravaran H et al. (2022) Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. J. Med. Virol. 94: 263-271.
28. Shchetinin E, Baturin V, Arushanyan E et al. (2022) Potential and possible therapeutic effects of melatonin on SARS-CoV-2 infection. Antioxidants (Basel) 11: 140.
29. Hasan ZT, Atrakji D, Mehuaiden DAK (2022) The Effect of Melatonin on thrombosis, sepsis and mortality rate in COVID-19 patients. Int. J. Infect. Dis. 114: 79-84.
30. El-Missiry MA, El-Missiry ZMA, Othman AI (2020) Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19. Eur. J. Pharmacol. 882: 173329.
31. Sileri P, Sica GS, Gentileschi P et al. (2004) Melatonin reduces bacterial translocation after intestinal ischemia-reperfusion injury. Transplant. Proc. 36: 2944-2946.
32. Parlakpinar H, Polat S, Acet HA (2021) Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin. Fundam. Clin. Pharmacol. 35: 62-75.
33. Menczel Schrire Z, Phillips CL, Chapman JL et al. (2022) Safety of higher doses of melatonin in adults: A systematic review and meta-analysis. J. Pineal Res. 72: e12782.
34. Acuña-Castroviejo D, Escames G, Figueira JC et al. (2020) Clinical trial to test the efficacy of melatonin in COVID-19. J. Pineal Res. 69: e12683.
35. Rodríguez-Rubio M, Figueira JC, Acuña-Castroviejo D et al. (2020) A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial. Trials 21: 699.
36. Ziaei A, Davoodian P, Dadvand H et al. (2020) Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 21: 882.
37. Cardinali DP (2021) Melatonin and healthy aging. Vitam. Horm. 115: 67-88.
38. Zhang R, Wang X, Ni L et al. (2020) COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 250: 117583.
39. Galano A, Tan DX, Reiter RJ (2011) Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal Res. 51: 1-16.
40. Reiter RJ (1997) Aging and oxygen toxicity: Relation to changes in melatonin. Age (Omaha) 20: 201-213.
41. Reiter R, Tang L, Garcia JJ et al. (1997) Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 60: 2255-2271.
42. Liu Z, Gan L, Xu Y et al. (2017) Melatonin alleviates inflammasome-induced pyroptosis through inhibiting NF-κB/GSDMD signal in mice adipose tissue. J. Pineal Res. 63: e12414.
43. Touitou Y, Reinberg A, Touitou D (2017) Association between light at night, melatonin secretion, sleep deprivation, and the internal clock: Health impacts and mechanisms of circadian disruption. Life Sci. 173: 94-106.
44. Chahbouni M, López MDS, Molina-Carballo A et al. (2017) Melatonin treatment reduces oxidative damage and normalizes plasma pro-inflammatory cytokines in patients suffering from charcot-marie-tooth neuropathy: A pilot study in three children. Molecules 22: 1728.
45. Uberos J, Augustin-Morales MC, Molina Carballo A et al. (2011) Normalization of the sleep-wake pattern and melatonin and 6-sulphatoxy-melatonin levels after a therapeutic trial with melatonin in children with severe epilepsy. J. Pineal Res. 50: 192-196.
46. Muñoz-Hoyos A, Sánchez-Forte M, Molina-Carballo A et al. (1998) Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. J. Child. Neurol. 13: 501-509.
47. Acuña-Castroviejo D, Escames G, Macías M et al. (1995) Cell protective role of melatonin in the brain. J. Pineal Res. 19: 57-63.
48. Liu H, Wang F, Zhao J et al. (2022) The effect and mechanisms of melatonin on the proliferation and apoptosis of lung cancer cells. Bioengineered 13: 3462-3469.
49. Muñoz A, Palomo EJ, Jerez-Calero A (2019) Use of an ANN to value MTF and melatonin effect on ADHD affected children. IEEE Access 7: 127254-127264.
50. Checa-Ros A, Muñoz-Hoyos A, Molina-Carballo A et al. (2017) Analysis of different melatonin secretion patterns in children with sleep disorders: melatonin secretion patterns in children. J. Child. Neurol. 32: 1000-1008.
51. Checa-Ros A, Muñoz-Gallego A, Muñoz-Gallego M et al. (2018) Clinical considerations derived from the administration of melatonin to children with sleep disorders. Pediatr. Neurol. 78: 61-69.
52. Zhao D, Yu Y, Shen Y et al. (2019) Melatonin synthesis and function: evolutionary history in animals and plants. Front. Endocrinol. (Lausanne) 10: 249.
53. Reiter RJ (1991) Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12: 151-180.
54. Tan DX, Manchester LC, Reiter RJ et al. (1999) Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim. Biophys. Acta 1472: 206-214.
55. Acuña-Castroviejo D, Pablos MI, Menendez-Pelaez A et al. (1993) Melatonin receptors in purified cell nuclei of liver. Res. Commun. Chem. Pathol. Pharmacol. 82: 253-256.
56. Acuña Castroviejo D, Escames G, Carazo A et al. (2002) Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr. Top. Med. Chem. 2: 133-151.
57. Morgan PJ, Barrett P, Howell HE et al. (1994) Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem. Int. 24: 101-146.
58. Dubocovich ML (1995) Melatonin receptors: are there multiple subtypes? Trends Pharmacol. Sci. 16: 50-56.
59. Benítez-King G, Antón-Tay F (1993) Calmodulin mediates melatonin cytoskeletal effects. Experientia 49: 635-641.
60. Becker-André M, Wiesenberg I, Schaeren-Wiemers N et al. (1994) Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J. Biol. Chem. 269: 28531-28534.
61. Ekmekcioglu C (2006) Melatonin receptors in humans: biological role and clinical relevance. Biomed. Pharmacother. 60: 97-108.
62. He F, Wu X, Zhang Q et al. (2021) Bacteriostatic potential of melatonin: therapeutic standing and mechanistic insights. Front. Immunol. 12: 683879.
63. Reiter RJ, Rosales-Corral S, Tan DX et al. (2017) Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas. Cell Mol. Life Sci. 74: 3863-3881.
64. Bubenik GA (2001) Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol. Signals Recept. 10: 350-366.
65. Carvalho-Sousa CE, Pereira EP, Kinker GS et al. (2020) Immune-pineal axis protects rat lungs exposed to polluted air. J. Pineal Res. 68: e12636.
66. Woo YD, Jeong D, Chung DH (2021) Development and functions of alveolar macrophages. Mol. Cells 44: 292-300.
67. Rubins JB (2003) Alveolar macrophages: wielding the double-edged sword of inflammation. Am. J. Respir. Crit. Care Med. 167: 103-104.
68. Schagat TL, Wofford JA, Wright JR (2001) Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J. Immunol. 166: 2727-2733.
69. Knapp S, Leemans JC, Florquin S et al. (2003) Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am. J. Respir. Crit. Care Med. 167: 171-179.
70. Gibbs JL, Dallon BW, Lewis JB et al. (2019) Diesel exhaust particle exposure compromises alveolar macrophage mitochondrial bioenergetics. Int. J. Mol. Sci. 20: 5598.
71. Slominski A, Tobin DJ, Zmijewski MA et al. (2008) Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol. Metab. 19: 17-24.
72. Fernandes PA, Kinker GS, Navarro BV et al. (2021) Melatonin-Index as a biomarker for predicting the distribution of presymptomatic and asymptomatic SARS-CoV-2 carriers. Melatonin Res, 4: 189-205.
73. Xia D, Yang L, Li Y et al. (2021) Melatonin alleviates Ochratoxin A-induced liver inflammation involved intestinal microbiota homeostasis and microbiota-independent manner. J. Hazard. Mater. 413: 125239.
74. Bonmati-Carrion MA, Tomas-Loba A (2021) Melatonin and cancer: A polyhedral network where the source matters. Antioxidants (Basel) 10: 210.
75. Castrillón PO, Esquifino AI, Varas A et al. (2000) Effect of melatonin treatment on 24-h variations in responses to mitogens and lymphocyte subset populations in rat submaxillary lymph nodes. J. Neuroendocrinol. 12: 758-765.
76. Ramos A, Míguez MP, Morgado S et al. (2018) Melatonin enhances responsiveness to Dichelobacter nodosus vaccine in sheep and increases peripheral blood CD4 T lymphocytes and IgG-expressing B lymphocytes. Vet. Immunol. Immunopathol. 206: 1-8.
77. Gurunathan S, Kang M-H, Choi Y et al. (2021) Melatonin: A potential therapeutic agent against COVID-19. Melatonin Res, 4: 30-69.
78. Shiu SY, Reiter RJ, Tan DX et al. (2003) Urgent search for safe and effective treatments of severe acute respiratory syndrome: is melatonin a promising candidate drug? J. Pineal Res. 35: 69-70.
79. Andersen LP, Gögenur I, Rosenberg J et al. (2016) The safety of melatonin in humans. Clin. Drug Investig. 36: 169-175.
80. Seabra ML, Bignotto M, Pinto LR, Jr. et al. (2000) Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J. Pineal Res. 29: 193-200.
81. Citera G, Arias MA, Maldonado-Cocco JA et al. (2000) The effect of melatonin in patients with fibromyalgia: a pilot study. Clin. Rheumatol. 19: 9-13.
82. Sánchez-Barceló EJ, Mediavilla MD, Tan DX et al. (2010) Clinical uses of melatonin: evaluation of human trials. Curr. Med. Chem. 17: 2070-2095.
83. Sehirli AO, Sayiner S, Serakinci N (2020) Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147). Mol. Biol. Rep. 47: 8229-8233.
84. Maestroni GJ (1993) The immunoneuroendocrine role of melatonin. J. Pineal Res. 14: 1-10.
85. Huang SH, Cao XJ, Liu W et al. (2010) Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice. J. Pineal Res. 48: 109-116.
86. Cardinali DP, Brown GM, Reiter RJ et al. (2020) Elderly as a high-risk group during COVID-19 pandemic: Effect of circadian misalignment, sleep dysregulation and melatonin administration. sleep vigil. 4: 81-87.
87. Nunes Oda S, Pereira Rde S (2008) Regression of herpes viral infection symptoms using melatonin and SB-73: comparison with Acyclovir. J. Pineal Res. 44: 373-378.
88. Boga JA, Coto-Montes A, Rosales-Corral SA et al. (2012) Beneficial actions of melatonin in the management of viral infections: a new use for this "molecular handyman"? Rev. Med. Virol. 22: 323-338.
89. Reiter RJ, Tan DX, Sainz RM et al. (2002) Melatonin: reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol. 54: 1299-1321.
90. Balduini W, Weiss MD, Carloni S et al. (2019) Melatonin pharmacokinetics and dose extrapolation after enteral infusion in neonates subjected to hypothermia. J. Pineal Res. 66: e12565.
91. Besag FMC, Vasey MJ, Lao KSJ et al. (2019) Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: A systematic review. CNS Drugs 33: 1167-1186.
92. Artigas L, Coma M, Matos-Filipe P et al. (2020) In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS One 15: e0240149.
93. Yeum KJ, Russell RM, Krinsky NI et al. (2004) Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch. Biochem. Biophys. 430: 97-103.
94. Jamilian M, Foroozanfard F, Mirhosseini N et al. (2019) Effects of melatonin supplementation on hormonal, inflammatory, genetic, and oxidative stress parameters in women with polycystic ovary syndrome. Front. Endocrinol. (Lausanne) 10: 273.
95. Daneshvar Kakhaki R, Ostadmohammadi V, Kouchaki E et al. (2020) Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Clin. Neurol. Neurosurg. 195: 105878.
96. Estaras M, Moreno N, Santofimia-Castaño P et al. (2019) Melatonin induces reactive oxygen species generation and changes in glutathione levels and reduces viability in human pancreatic stellate cells. J. Physiol. Biochem. 75: 185-197.
97. Fischer TW, Scholz G, Knöll B et al. (2004) Melatonin suppresses reactive oxygen species induced by UV irradiation in leukocytes. J. Pineal Res. 37: 107-112.
98. Fulia F, Gitto E, Cuzzocrea S et al. (2001) Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J. Pineal Res. 31: 343-349.
99. Allegra M, Gentile C, Tesoriere L et al. (2002) Protective effect of melatonin against cytotoxic actions of malondialdehyde: an in vitro study on human erythrocytes. J. Pineal Res. 32: 187-193.
100. Ziaadini F, Aminae M, Rastegar MM et al. (2017) Melatonin supplementation decreases aerobic exercise training induced-lipid peroxidation and malondialdehyde in sedentary young women. Polish J. Food Nutr. Sci. 67: 225-232.
101. Reina M, Martínez A (2018) A new free radical scavenging cascade involving melatonin and three of its metabolites (3OHM, AFMK and AMK). Computational Theoretical Chem. 1123: 111-118.
102. Goc Z, Szaroma W, Kapusta E et al. (2017) Protective effects of melatonin on the activity of SOD, CAT, GSH-Px and GSH content in organs of mice after administration of SNP. Chin. J. Physiol. 60: 1-10.
103. Purushothaman A, Sheeja AA, Janardanan D (2020) Hydroxyl radical scavenging activity of melatonin and its related indolamines. Free Radic. Res. 54: 373-383.
104. Mehrzadi S, Safa M, Kamrava SK et al. (2017) Protective mechanisms of melatonin against hydrogen-peroxide-induced toxicity in human bone-marrow-derived mesenchymal stem cells. Can. J. Physiol. Pharmacol. 95: 773-786.
105. Loren P, Sánchez R, Arias ME et al. (2017) Melatonin scavenger properties against oxidative and nitrosative stress: impact on gamete handling and in vitro embryo production in humans and other mammals. Int. J. Mol. Sci. 18: 1119.
106. Fan W, He Y, Guan X et al. (2018) Involvement of the nitric oxide in melatonin-mediated protection against injury. Life Sci. 200: 142-147.
107. Hardeland R (2017) Taxon- and Site-specific melatonin catabolism. Molecules 22: 2015.
108. Ayala A, Muñoz MF, Argüelles S (2014) Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell Longev. 2014: 360438.
109. Morvaridzadeh M, Sadeghi E, Agah S et al. (2020) Effect of melatonin supplementation on oxidative stress parameters: A systematic review and meta-analysis. Pharmacol. Res. 161: 105210.
110. Erat M, Ciftci M (2006) Effect of melatonin on enzyme activities of glutathione reductase from human erythrocytes in vitro and from rat erythrocytes in vivo. Eur. J. Pharmacol. 537: 59-63.
111. Fischer TW, Kleszczyński K, Hardkop LH et al. (2013) Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the formation of DNA damage (8-hydroxy-2'-deoxyguanosine) in ex vivo human skin. J. Pineal Res. 54: 303-312.
112. Pierrefiche G, Laborit H (1995) Oxygen free radicals, melatonin, and aging. Exp. Gerontol. 30: 213-227.
113. Ciftçi M, Bilici D, Küfrevioğlu OI (2001) Effects of melatonin on enzyme activities of glucose-6-phosphate dehydrogenase from human erythrocytes in vitro and from rat erythrocytes in vivo. Pharmacol. Res. 44: 7-11.
114. Gupta M, Gupta YK, Agarwal S et al. (2004) A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. Br. J. Clin. Pharmacol. 58: 542-547.
115. Okatani Y, Wakatsuki A, Shinohara K et al. (2001) Melatonin stimulates glutathione peroxidase activity in human chorion. J. Pineal Res. 30: 199-205.
116. Sharafati-Chaleshtori R, Shirzad H, Rafieian-Kopaei M et al. (2017) Melatonin and human mitochondrial diseases. J. Res. Med. Sci. 22: 2.
117. Ozturk G, Coşkun S, Erbaş D et al. (2000) The effect of melatonin on liver superoxide dismutase activity, serum nitrate and thyroid hormone levels. Jpn. J. Physiol. 50: 149-153.
118. Madsen-Bouterse SA, Zhong Q, Mohammad G et al. (2010) Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase. Free Radic. Res. 44: 313-321.
119. Majima HJ, Oberley TD, Furukawa K et al. (1998) Prevention of mitochondrial injury by manganese superoxide dismutase reveals a primary mechanism for alkaline-induced cell death. J. Biol. Chem. 273: 8217-8224.
120. Suwanjang W, Abramov AY, Charngkaew K et al. (2016) Melatonin prevents cytosolic calcium overload, mitochondrial damage and cell death due to toxically high doses of dexamethasone-induced oxidative stress in human neuroblastoma SH-SY5Y cells. Neurochem. Int .97: 34-41.
121. Genario R, Morello E, Bueno AA et al. (2019) The usefulness of melatonin in the field of obstetrics and gynecology. Pharmacol. Res. 147: 104337.
122. Hardeland R (2018) Melatonin and inflammation-story of a double-edged blade. J. Pineal Res. 65: e12525.
123. Wang QL, Yang L, Peng Y et al. (2019) Ginsenoside Rg1 regulates SIRT1 to ameliorate sepsis-induced lung inflammation and injury via inhibiting endoplasmic reticulum stress and inflammation. Mediators Inflamm. 2019: 6453296.
124. Sun CK, Lee FY, Kao YH et al. (2015) Systemic combined melatonin-mitochondria treatment improves acute respiratory distress syndrome in the rat. J. Pineal Res. 58: 137-150.
125. Ling Y, Li ZZ, Zhang JF et al. (2018) MicroRNA-494 inhibition alleviates acute lung injury through Nrf2 signaling pathway via NQO1 in sepsis-associated acute respiratory distress syndrome. Life Sci. 210: 1-8.
126. Pedrosa AM, Weinlich R, Mognol GP et al. (2010) Melatonin protects CD4+ T cells from activation-induced cell death by blocking NFAT-mediated CD95 ligand upregulation. J. Immunol. 184: 3487-3494.
127. Shang Y, Xu SP, Wu Y et al. (2009) Melatonin reduces acute lung injury in endotoxemic rats. Chin. Med. J. (Engl) 122: 1388-1393.
128. Ahmadi Z, Ashrafizadeh M (2020) Melatonin as a potential modulator of Nrf2. Fundam. Clin. Pharmacol. 34: 11-19.
129. Habtemariam S, Daglia M, Sureda A et al. (2017) Melatonin and respiratory diseases: A review. Curr. Top. Med. Chem. 17: 467-488.
130. Hardeland R (2019) Aging, melatonin, and the pro- and anti-inflammatory networks. Int. J. Mol. Sci. 20: 1223.
131. Carrascal L, Nunez-Abades P, Ayala A et al. (2018) Role of melatonin in the inflammatory process and its therapeutic potential. Curr. Pharm. Des. 24: 1563-1588.
132. Bazyar H, Gholinezhad H, Moradi L et al. (2019) The effects of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and inflammatory markers in type 2 diabetes mellitus patients with chronic periodontitis: a double-blind, placebo-controlled trial. Inflammopharmacology 27: 67-76.
133. Sánchez-López AL, Ortiz GG, Pacheco-Moises FP et al. (2018) Efficacy of melatonin on serum pro-inflammatory cytokines and oxidative stress markers in relapsing remitting multiple sclerosis. Arch. Med. Res. 49: 391-398.
134. Kücükakin B, Lykkesfeldt J, Nielsen HJ et al. (2008) Utility of melatonin to treat surgical stress after major vascular surgery--a safety study. J. Pineal Res. 44: 426-431.
135. Zhao Z, Lu C, Li T et al. (2018) The protective effect of melatonin on brain ischemia and reperfusion in rats and humans: In vivo assessment and a randomized controlled trial. J. Pineal Res. 65: e12521.
136. Shafiei E, Bahtoei M, Raj P et al. (2018) Effects of N-acetyl cysteine and melatonin on early reperfusion injury in patients undergoing coronary artery bypass grafting: A randomized, open-labeled, placebo-controlled trial. Medicine (Baltimore) 97: e11383.
137. Zarezadeh M, Khorshidi M, Emami M et al. (2020) Melatonin supplementation and pro-inflammatory mediators: a systematic review and meta-analysis of clinical trials. Eur. J. Nutr. 59: 1803-1813.
138. Reiter RJ, Abreu-Gonzalez P, Marik PE et al. (2020) Therapeutic algorithm for use of melatonin in patients with COVID-19. Front. Med. (Lausanne) 7: 226.
139. Yang CY, Chen CS, Yiang GT et al. (2018) New insights into the immune molecular regulation of the pathogenesis of acute respiratory distress syndrome. Int. J. Mol. Sci. 19: 588.
140. Tan DX, Hardeland R (2020) Targeting host defense system and rescuing compromised mitochondria to increase tolerance against pathogens by melatonin may impact outcome of deadly virus infection pertinent to COVID-19. Molecules 25: 4410.
141. Sygitowicz G, Sitkiewicz D (2020) Molecular mechanisms of organ damage in sepsis: an overview. Braz J. Infect. Dis. 24: 552-560.
142. Luo J, Song J, Zhang H et al. (2018) Melatonin mediated Foxp3-downregulation decreases cytokines production via the TLR2 and TLR4 pathways in H. pylori infected mice. Int. Immunopharmacol. 64: 116-122.
143. Jauhari A, Baranov SV, Suofu Y et al. (2020) Melatonin inhibits cytosolic mitochondrial DNA-induced neuroinflammatory signaling in accelerated aging and neurodegeneration. J. Clin. Invest. 130: 3124-3136.
144. Xu X, Wang G, Ai L et al. (2018) Melatonin suppresses TLR9-triggered proinflammatory cytokine production in macrophages by inhibiting ERK1/2 and AKT activation. Sci. Rep. 8: 15579.
145. Feng R, Adeniran SO, Huang F et al. (2022) The ameliorative effect of melatonin on LPS-induced Sertoli cells inflammatory and tight junctions damage via suppression of the TLR4/MyD88/NF-κB signaling pathway in newborn calf. Theriogenology 179: 103-116.
146. Tate MD, Ong JDH, Dowling JK et al. (2016) Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Sci. Rep. 6: 27912.
147. Wu X, Ji H, Wang Y et al. (2019) Melatonin alleviates radiation-induced lung injury via regulation of miR-30e/NLRP3 axis. Oxid. Med. Cell Longev. 2019: 4087298.
148. Wu HM, Xie QM, Zhao CC et al. (2019) Melatonin biosynthesis restored by CpG oligodeoxynucleotides attenuates allergic airway inflammation via regulating NLRP3 inflammasome. Life Sci. 239: 117067.
149. Zhang Y, Li X, Grailer JJ et al. (2016) Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J. Pineal Res. 60: 405-414.
150. Ren DL, Sun AA, Li YJ et al. (2015) Exogenous melatonin inhibits neutrophil migration through suppression of ERK activation. J. Endocrinol. 227: 49-60.
151. Maldonado MD, Mora-Santos M, Naji L et al. (2010) Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol. Res. 62: 282-287.
152. Muxel SM, Pires-Lapa MA, Monteiro AW et al. (2012) NF-κB drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-N-acetyltransferase (AA-NAT) gene. PLoS One 7: e52010.
153. Maldonado MD, García-Moreno H, González-Yanes C et al. (2016) Possible involvement of the inhibition of NF-κB factor in anti-inflammatory actions that melatonin exerts on mast cells. J. Cell Biochem. 117: 1926-1933.
154. Hasan MZ, Islam S, Matsumoto K et al. (2021) Meta-analysis of single-cell RNA-seq data reveals phenotypic switching of immune cells in severe COVID-19 patients. Comput. Biol. Med. 137: 104792.
155. Reiter RJ, Sharma R, Ma Q et al. (2020) Plasticity of glucose metabolism in activated immune cells: advantages for melatonin inhibition of COVID-19 disease. Melatonin Res. 3,:362–379.
156. Duan F, Guo L, Yang L et al. (2020) Modeling COVID-19 with human pluripotent stem cell-derived cells reveals synergistic effects of anti-inflammatory macrophages with ACE2 inhibition Against SARS-CoV-2. Res. Sq. 3: rs-62758.
157. Cuesta A, Cerezuela R, Esteban MA et al. (2008) In vivo actions of melatonin on the innate immune parameters in the teleost fish gilthead seabream. J. Pineal Res. 45: 70-78.
158. Crespo I, Fernández-Palanca P, San-Miguel B et al. (2020) Melatonin modulates mitophagy, innate immunity and circadian clocks in a model of viral-induced fulminant hepatic failure. J. Cell Mol. Med. 24: 7625-7636.
159. Foley HM, Steel AE (2019) Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence. Complement. Ther. Med. 42: 65-81.
160. Mills E, Wu P, Seely D et al. (2005) Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J. Pineal Res. 39: 360-366.
161. Herxheimer A, Petrie KJ (2002) Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst. Rev: Cd001520.
162. Alghamdi BS (2018) The neuroprotective role of melatonin in neurological disorders. J. Neurosci. Res. 96: 1136-1149.
163. Jerez-Calero A, Salvatierra-Cuenca MT, Benitez-Feliponi Á et al. (2020) Hypothermia plus melatonin in asphyctic newborns: A randomized-controlled pilot study. Pediatr. Crit. Care Med. 21: 647-655.
164. Leonardo-Mendonça RC, Martinez-Nicolas A, de Teresa Galván C et al. (2015) The benefits of four weeks of melatonin treatment on circadian patterns in resistance-trained athletes. Chronobiol. Int. 32: 1125-1134.
165. Jahnke G, Marr M, Myers C et al. (1999) Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol. Sci. 50: 271-279.
166. Cardinali DP, Srinivasan V, Brzezinski A et al. (2012) Melatonin and its analogs in insomnia and depression. J. Pineal Res. 52: 365-375.
167. Härtter S, Nordmark A, Rose DM et al. (2003) Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br. J. Clin. Pharmacol. 56: 679-682.
168. Härtter S, Grözinger M, Weigmann H et al. (2000) Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin. Pharmacol. Ther. 67: 1-6.
169. Hilli J, Korhonen T, Turpeinen M et al. (2008) The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism. J. Clin. Pharmacol. 48: 986-994.
170. Ursing C, von Bahr C, Brismar K et al. (2005) Influence of cigarette smoking on melatonin levels in man. Eur. J. Clin. Pharmacol. 61: 197-201.
171. Otmani S, Demazières A, Staner C et al. (2008) Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum. Psychopharmacol. 23: 693-705.
172. Andersen LP, Werner MU, Rosenberg J et al. (2014) A systematic review of peri-operative melatonin. Anaesthesia 69: 1163-1171.
173. Brzezinski A, Vangel MG, Wurtman RJ et al. (2005) Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med. Rev. 9: 41-50.
174. Kehlet H, Wilmore DW (2008) Evidence-based surgical care and the evolution of fast-track surgery. Ann. Surg. 248: 189-198.
175. Lader M (2014) Benzodiazepine harm: how can it be reduced? Br. J. Clin. Pharmacol. 77: 295-301.
176. Kehlet H (2005) Postoperative opioid sparing to hasten recovery: what are the issues? Anesthesiology 102: 1083-1085.
177. Ingrasciotta Y, Sultana J, Giorgianni F et al. (2015) Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One 10: e0122899.
178. Lanas Á, Carrera-Lasfuentes P, Arguedas Y et al. (2015) Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin. Gastroenterol. Hepatol. 13: 906-912.e902.
179. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J et al. (2011) Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 123: 2226-2235.
180. Barthélémy O, Limbourg T, Collet JP et al. (2013) Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. Int. J. Cardiol. 163: 266-271.
181. Klein M, Gögenur I, Rosenberg J (2012) Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: cohort study based on prospective data. BMJ 345: e6166.
182. Davis GF (1986) Adverse effects of corticosteroids: II. Systemic. Clin. Dermatol. 4: 161-169.
183. Ferracioli-Oda E, Qawasmi A, Bloch MH (2018) Meta-analysis: Melatonin for the treatment of primary sleep disorders. Focus (Am Psychiatr Publ) 16: 113-118.
184. Genario R, Giacomini A, de Abreu MS et al. (2020) Sex differences in adult zebrafish anxiolytic-like responses to diazepam and melatonin. Neurosci. Lett. 714: 134548.
185. Harpsøe NG, Andersen LP, Gögenur I et al. (2015) Clinical pharmacokinetics of melatonin: a systematic review. Eur. J. Clin. Pharmacol. 71: 901-909.
186. Ramos E, Farré-Alins V, Egea J et al. (2020) Melatonin's efficacy in stroke patients; a matter of dose? A systematic review. Toxicol. Appl. Pharmacol. 392: 114933.
187. 187. Sugden D (1983) Psychopharmacological effects of melatonin in mouse and rat. J. Pharmacol. Exp. Ther. 227: 587-591.
188. Mehrzadi S, Karimi MY, Fatemi A et al. (2021) SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin. Pharmacol. Ther. 224: 107825.
Published
2023-09-30
How to Cite
[1]
Molina-Carballo, A., Jerez-Calero, A., Fernández-López, L., Augustin-Morales, M. del C., Muñoz-Hoyos, A. and Agil, A. 2023. The preventive and protective role of melatonin in SARS-CoV-2 infection: a retrospective study. Melatonin Research. 6, 3 (Sep. 2023), 372-396. DOI:https://doi.org/https://doi.org/10.32794/mr112500159.
Section
Research Articles